Paul CalÃ"s

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9511007/publications.pdf

Version: 2024-02-01

194 12,308 56 106
papers citations h-index g-index

213 213 213 10657 all docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis. BMC Infectious Diseases, 2022, 22, 94.	1.3	6
2	ABO blood group does not influence Childâ€Pugh A cirrhosis outcome: An observational studyÂfrom CIRRAL and ANRS CO12 CIRVIR cohorts. Liver International, 2022, 42, 1386-1400.	1.9	2
3	Comparison of screening strategies with two new tests to score and diagnose varices needing treatment. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101925.	0.7	2
4	Systematic screening for advanced liver fibrosis in patients with coronary artery disease: The CORONASH study. PLoS ONE, 2022, 17, e0266965.	1.1	4
5	Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment. Clinical Gastroenterology and Hepatology, 2021, 19, 777-787.e17.	2.4	19
6	Nonâ€selective betaâ€blockers increase overall and liver mortality in alcoholic cirrhosis with MELDÂ≥Â12 over 5 years of followâ€up. Liver International, 2021, 41, 168-179.	1.9	4
7	Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. Journal of Hepatology, 2021, 74, 1109-1116.	1.8	112
8	Laser ablation of microdroplets for copper isotopic analysis <i>via</i> MC-ICP-MS. Analysis of serum microsamples for the diagnosis and follow-up treatment of Wilson's disease. Journal of Analytical Atomic Spectrometry, 2021, 36, 968-980.	1.6	13
9	Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101713.	0.7	10
10	Liver fibrosis staging by computed tomography: prospective randomized multicentric evaluation of image analyses. Clinics and Research in Hepatology and Gastroenterology, 2021, 46, 101797.	0.7	3
11	Crossâ€linkage between bacterial taxonomy and gene functions: a study of metagenomeâ€assembled genomes of gut microbiota in adult nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2021, 53, 722-732.	1.9	7
12	Simple blood fibrosis tests reduce unnecessary referrals for specialized evaluations of liver fibrosis in NAFLD and ALD patients. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 349-355.	0.7	3
13	A novel spleenâ€dedicated stiffness measurement by FibroScan® improves the screening of highâ€risk oesophageal varices. Liver International, 2020, 40, 175-185.	1.9	60
14	Non-invasive diagnosis of variceal bleeding: choose the right target population and identify the right culprit. Annals of Translational Medicine, 2020, 8, 774-774.	0.7	0
15	COVID-19 infection in first trimester of pregnancy marked by a liver cytolysis in a woman previously treated by hydroxychloroquine for repeated implantation failure: a case report. BMC Infectious Diseases, 2020, 20, 845.	1.3	4
16	Personalized surveillance for hepatocellular carcinoma in cirrhosis– using machine learning adapted to HCV status. Journal of Hepatology, 2020, 73, 1434-1445.	1.8	52
17	A pragmatic non-invasive assessment of liver fibrosis in patients with psoriasis, rheumatoid arthritis or Crohn's disease receiving methotrexate therapy. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 100003.	0.7	14
18	How to clarify the Baveno <scp>VI</scp> criteria for ruling out varices needing treatment by noninvasive tests. Liver International, 2019, 39, 49-53.	1.9	21

#	Article	IF	CITATIONS
19	Criteria to Determine Reliability of Noninvasive Assessment of Liver Fibrosis With Virtual Touch Quantification. Clinical Gastroenterology and Hepatology, 2019, 17, 164-171.e5.	2.4	11
20	Direct comparison of the specialised blood fibrosis tests FibroMeter ^{V2G} and Enhanced Liver Fibrosis score in patients with nonâ€alcoholic fatty liver disease from tertiary care centres. Alimentary Pharmacology and Therapeutics, 2019, 50, 1214-1222.	1.9	38
21	New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD. Journal of Hepatology, 2019, 71, 389-396.	1.8	107
22	Obstructive sleep apnoea and non-alcoholic fatty liver disease: Which patients should be referred to hepatologists?. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, e90-e92.	0.7	1
23	Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy. Gastroenterology, 2019, 156, 997-1009.e5.	0.6	100
24	Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet, The, 2019, 393, 1453-1464.	6.3	449
25	Screening for therapeutic trials and treatment indication in clinical practice: <scp>MACK</scp> â€3, a new blood test for the diagnosis of fibrotic <scp>NASH</scp> . Alimentary Pharmacology and Therapeutics, 2018, 47, 1387-1396.	1.9	55
26	A single blood test adjusted for different liver fibrosis targets improves fibrosis staging and especially cirrhosis diagnosis. Hepatology Communications, 2018, 2, 455-466.	2.0	4
27	A Novel FibroScan Examination Dedicated to Spleen Stiffness Measurement. Ultrasound in Medicine and Biology, 2018, 44, 1616-1626.	0.7	27
28	Large oesophageal varice screening by a sequential algorithm using a cirrhosis blood test and optionally capsule endoscopy. Liver International, 2018, 38, 84-93.	1.9	27
29	Reply to: "Pitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FM VCTE algorithm―and to "Application of the new eLIFT test for the non-invasive diagnosis of advanced liver fibrosis in people with type 2 diabetes― Journal of Hepatology, 2018, 68, 605-606.	1.8	0
30	The noninvasive diagnosis of esophageal varices and its application in clinical practice. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 6-16.	0.7	13
31	Doppler ultrasonography devices, including elastography, allow for accurate diagnosis of severe liver fibrosis. European Journal of Radiology, 2018, 108, 133-139.	1.2	5
32	Increased liver stiffness in patients with severe sleep apnoea and metabolic comorbidities. European Respiratory Journal, 2018, 51, 1800601.	3.1	23
33	A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. Journal of Hepatology, 2017, 66, 1158-1165.	1.8	71
34	Liver fibrosis diagnosis by blood test and elastography in chronic hepatitis C: agreement or combination?. Alimentary Pharmacology and Therapeutics, 2017, 45, 991-1003.	1.9	16
35	Editorial: combining elastography with blood test for fibrosis assessment in chronic hepatitis C – authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 1276-1277.	1.9	0
36	A Single Test Combining Blood Markers and Elastography is More Accurate Than Other Fibrosis Tests in the Main Causes of Chronic Liver Diseases. Journal of Clinical Gastroenterology, 2017, 51, 639-649.	1.1	26

#	#	Article	IF	CITATIONS
Š	37	Performance of FibroScan \hat{A}^{\otimes} to detect large esophageal varices in chronic liver diseases is improved by a novel spleen-dedicated examination. Journal of Hepatology, 2017, 66, S374.	1.8	4
ć	38	Metabolic and hepatic effects of bloodletting in dysmetabolic iron overload syndrome: A randomized controlled study in 274 patients. Hepatology, 2017, 65, 465-474.	3.6	45
ę		Fibrosis assessment using FibroMeter combined to first generation tests in hepatitis C. World Journal of Hepatology, 2017, 9, 310.	0.8	6
4	40	Automatic detection of cirrhosis in hospitalized patients. European Journal of Gastroenterology and Hepatology, 2016, 28, 74-81.	0.8	O
4		Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. Hepatology, 2016, 63, 1817-1827.	3.6	388
2	42	Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1750-1756.	1.4	15
2	43	Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. Journal of Hepatology, 2016, 65, 570-578.	1.8	300
	44	Association Between Severity of Obstructive Sleep Apnea and Blood Markers of Liver Injury. Clinical Gastroenterology and Hepatology, 2016, 14, 1657-1661.	2.4	37
2	45	Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). Hepatology, 2016, 64, 1136-1147.	3.6	75
2	46	The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology, 2016, 63, 764-775.	3.6	1,029
4	47	Cirrhosis Diagnosis and Liver Fibrosis Staging. Journal of Clinical Gastroenterology, 2015, 49, 512-519.	1.1	7
2	48	Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir) Tj ETQq0 0 0 rgBT	/9.yerlock	10 Tf 50 30
4	49	IL-26 is overexpressed in chronically HCV-infected patients and enhances TRAIL-mediated cytotoxicity and interferon production by human NK cells. Gut, 2015, 64, 1466-1475.	6.1	49
Ę	50	Screening of esophageal varices by esophageal capsule endoscopy: results of a French multicenter prospective study. Endoscopy, 2015, 47, 486-492.	1.0	33
	51	An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: The Liver-FibroSTARD standards. Journal of Hepatology, 2015, 62, 807-815.	1.8	54
ţ	52	Liver-FibroSTARD checklist and glossary: tools for standardized design and reporting of diagnostic accuracy studies of liver fibrosis tests. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1135-7.	1.4	3
{	53	Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding. Hepatology, 2015, 61, 1024-1032.	3.6	23
Ę		Automated morphometry provides accurate and reproducible virtual staging of liver fibrosis in chronic hepatitis C. Journal of Pathology Informatics, 2015, 6, 20.	0.8	11

#	Article	IF	CITATIONS
55	Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liverâ€prognosis in chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 2014, 40, 178-188.	1.9	36
56	ILâ€34 and macrophage colonyâ€stimulating factor are overexpressed in hepatitis C virus fibrosis and induce profibrotic macrophages that promote collagen synthesis by hepatic stellate cells. Hepatology, 2014, 60, 1879-1890.	3.6	107
57	Precise evaluation of liver histology by computerized morphometry shows that steatosis influences liver stiffness measured by transient elastography in chronic hepatitis C. Journal of Gastroenterology, 2014, 49, 527-537.	2.3	53
58	Quantification of portal–bridging fibrosis area more accurately reflects fibrosis stage and liver stiffness than whole fibrosis or perisinusoidal fibrosis areas in chronic hepatitis C. Modern Pathology, 2014, 27, 1035-1045.	2.9	19
59	Improved fibrosis staging by elastometry and blood test in chronic hepatitis C. Liver International, 2014, 34, 907-917.	1.9	28
60	Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C. Hepatology, 2014, 60, 65-76.	3.6	118
61	Metastatic hepatocellular carcinoma: When surgery and successive palliative treatments lead to remission. Clinics and Research in Hepatology and Gastroenterology, 2014, 38, e19-e22.	0.7	3
62	AST/ALT ratio is not an index of liver fibrosis in chronic hepatitis C when aminotransferase activities are determinate according to the international recommendations. Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 467-472.	0.7	18
63	MRI measurement of liver fat content predicts the metabolic syndrome. Diabetes and Metabolism, 2013, 39, 314-321.	1.4	18
64	A major new step in nonâ€invasive evaluation of portal hypertension: elastography. Liver International, 2013, 33, 4-6.	1.9	2
65	Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology, 2013, 57, 1182-1191.	3.6	466
66	Renal macro- and microcirculation autoregulatory capacity during early sepsis and norepinephrine infusion in rats. Critical Care, 2013, 17, R139.	2.5	22
67	Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection. Annals of Internal Medicine, 2013, 159, 371.	2.0	1
68	Liver fibrosis in patients with non-alcoholic fatty liver disease: diagnostic options in clinical practice. Expert Opinion on Medical Diagnostics, 2012, 6, 381-394.	1.6	8
69	Can we precisely classify liver fibrosis without biopsy in hepatitis C?. Clinical Practice (London,) Tj ETQq1 1 0.7843	14.rgBT /0	Oyerlock 10
70	Controlled attenuation parameter (<scp>CAP</scp>): a new device for fast evaluation of liver fat?. Liver International, 2012, 32, 875-877.	1.9	24
71	1045 SEVERAL PATHOLOGICAL LESIONS INFLUENCE NON-INVASIVE TESTS OF LIVER FIBROSIS. Journal of Hepatology, 2012, 56, S408-S409.	1.8	2
72	The Osteopontin Level in Liver, Adipose Tissue and Serum Is Correlated with Fibrosis in Patients with Alcoholic Liver Disease. PLoS ONE, 2012, 7, e35612.	1.1	74

#	Article	IF	Citations
73	Fibrosis progression under maintenance interferon in hepatitis C is better detected by blood test than liver morphometry. Journal of Viral Hepatitis, 2012, 19, e143-53.	1.0	7
74	Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology, 2012, 55, 58-67.	3.6	112
75	Reply:. Hepatology, 2012, 55, 653-653.	3.6	0
76	Assessment of new hyaluronic acid assays and their impact on FibroMeter scores. Clinica Chimica Acta, 2011, 412, 347-352.	0.5	11
77	Steatosis degree, measured by morphometry, is linked to other liver lesions and metabolic syndrome components in patients with NAFLD. European Journal of Gastroenterology and Hepatology, 2011, 23, 974-981.	0.8	16
78	Comparison of accuracy of fibrosis degree classifications by liver biopsy and non-invasive tests in chronic hepatitis C. BMC Gastroenterology, 2011, 11, 132.	0.8	22
79	Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities. Hepatology, 2011, 54, 1987-1997.	3.6	309
80	A New Combination of Blood Test and Fibroscan for Accurate Non-Invasive Diagnosis of Liver Fibrosis Stages in Chronic Hepatitis C. American Journal of Gastroenterology, 2011, 106, 1255-1263.	0.2	87
81	Response to Munteanu et al American Journal of Gastroenterology, 2011, 106, 1853-1854.	0.2	0
82	The effects of vasopressin and its analogues on the liver and its disorders in the critically ill. Current Opinion in Critical Care, 2010, 16, 148-152.	1.6	11
83	Noninvasive liver steatosis quantification using MRI techniques combined with blood markers. European Journal of Gastroenterology and Hepatology, 2010, 22, 973-982.	0.8	24
84	Acoustic radiation force impulse: a new ultrasonographic technology for the widespread noninvasive diagnosis of liver fibrosis. European Journal of Gastroenterology and Hepatology, 2010, 22, 1074-1084.	0.8	126
85	Radiation-induced cholangitis with hepatocellular carcinoma. Gastroenterologie Clinique Et Biologique, 2010, 34, 35-39.	0.9	6
86	A not so solitary fibrous tumor of the liver. Gastroenterologie Clinique Et Biologique, 2010, 34, 716-720.	0.9	18
87	Optimization and robustness of blood tests for liver fibrosis and cirrhosis. Clinical Biochemistry, 2010, 43, 1315-1322.	0.8	42
88	Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease. Liver International, 2010, 30, 1346-1354.	1.9	41
89	Clinical interpretation of Fibroscan® results: a real challenge. Liver International, 2010, 30, 1400-1402.	1.9	14
90	Comparison of Elastography, Serum Marker Scores, and Histology for the Assessment of Liver Fibrosis in Hepatitis B Virus (HBV)-Infected Patients in Burkina Faso. American Journal of Tropical Medicine and Hygiene, 2010, 82, 454-458.	0.6	66

#	Article	IF	Citations
91	Effects of hydrogen sulfide on hemodynamics, inflammatory response and oxidative stress during resuscitated hemorrhagic shock in rats. Critical Care, 2010, 14, R165.	2.5	75
92	Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. Journal of Hepatology, 2010, 53, 238-244.	1.8	38
93	Resolution of chronic hepatitis Delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine. Journal of Clinical Virology, 2010, 47, 97-99.	1.6	21
94	Which would you prefer for a liver fibrosis test: A limited fixed menu or a gourmet buffet?. Gastroenterologie Clinique Et Biologique, 2009, 33, 388-389.	0.9	0
95	Combination of fibrosis tests: Sequential or synchronous?. Hepatology, 2009, 50, 656-657.	3.6	9
96	The combination of a blood test and Fibroscan improves the nonâ€invasive diagnosis of liver fibrosis. Liver International, 2009, 29, 1507-1515.	1.9	105
97	Comparison of blood tests for liver fibrosis specific or not to NAFLD. Journal of Hepatology, 2009, 50, 165-173.	1.8	230
98	Ultrasonographic elastometry vs. blood tests for the diagnosis of cirrhosis: A Pyrrhic victory?. Journal of Hepatology, 2009, 51, 228-229.	1.8	2
99	Treatment of liver fibrosis: Clinical aspects. Gastroenterologie Clinique Et Biologique, 2009, 33, 958-966.	0.9	7
100	Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. European Journal of Gastroenterology and Hepatology, 2009, 21, 28-38.	0.8	58
101	Detrimental hemodynamic and inflammatory effects of microparticles originating from septic rats*. Critical Care Medicine, 2009, 37, 2045-2050.	0.4	99
102	Reproducibility of blood tests of liver fibrosis in clinical practice. Clinical Biochemistry, 2008, 41, 10-18.	0.8	63
103	Factors Limiting Complete Tumor Ablation by Radiofrequency Ablation. CardioVascular and Interventional Radiology, 2008, 31, 107-115.	0.9	37
104	Hemodynamic effects of the early and long-term administration of propranolol in rats with intrahepatic portal hypertension. Hepatology International, 2008, 2, 457-464.	1.9	8
105	Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology, 2008, 47, 1453-1461.	3.6	80
106	Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: A meta-analysis with individual data. Clinical Biochemistry, 2008, 41, 1368-1376.	0.8	69
107	Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver International, 2008, 28, 1352-1362.	1.9	94
108	Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests. Gastroenterologie Clinique Et Biologique, 2008, 32, 1050-1060.	0.9	12

#	Article	IF	Citations
109	FibroMeters: a family of blood tests for liver fibrosis. Gastroenterologie Clinique Et Biologique, 2008, 32, 40-51.	0.9	47
110	Laser Doppler flowmetry in healthy rats: impact of isoflurane anesthetic on signal complexity. , 2008, , .		0
111	Actualités sur les co-infections VIH–VHC. Antibiotiques, 2008, 10, 167-175.	0.1	0
112	Internal Radiotherapy of Liver Cancer with Rat Hepatocarcinoma-Intestine-Pancreas Gene as a Liver Tumor-Specific Promoter. Human Gene Therapy, 2008, 19, 915-926.	1.4	28
113	Reproducibility of Liver Stiffness Measurement by Ultrasonographic Elastometry. Clinical Gastroenterology and Hepatology, 2008, 6, 1263-1269.	2.4	113
114	Vapreotide acetate for the treatment of esophageal variceal bleeding. Expert Review of Gastroenterology and Hepatology, 2008, 2, 185-192.	1.4	4
115	Learning curve and interobserver reproducibility evaluation of liver stiffness measurement by transient elastography. European Journal of Gastroenterology and Hepatology, 2008, 20, 693-701.	0.8	95
116	Laser Doppler flowmetry signals to quantify effects of isoflurane on the peripheral cardiovascular system of healthy rats. Applied Physics Letters, 2007, 91, 263901.	1.5	1
117	Intrafamilial hepatitis E in France. Journal of Clinical Virology, 2007, 39, 51-53.	1.6	9
118	Effect of Prolonged Interferon Therapy on the Outcome of Hepatitis C Virus–Related Cirrhosis: A Randomized Trial. Clinical Gastroenterology and Hepatology, 2007, 5, 502-507.	2.4	45
119	Physiopathologie de la cirrhose et de ses complications. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2007, 16, 557-562.	0.1	3
120	Sodium Iodide Symporter Is Expressed at the Preneoplastic Stages of Liver Carcinogenesis and in Human Cholangiocarcinoma. Gastroenterology, 2007, 132, 1495-1503.	0.6	24
121	In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel. International Journal of Pharmaceutics, 2007, 344, 143-149.	2.6	72
122	Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients. Haemophilia, 2007, 13, 722-729.	1.0	15
123	Fibrinogen angers with a new deletion (? GVYYQ 346-350) causes hypofibrinogenemia with hepatic storage. Journal of Thrombosis and Haemostasis, 2007, 5, 1999-2005.	1.9	38
124	Diagnosis and Measurement of Liver Fibrosis by MRI in Bile Duct Ligated Rats. Digestive Diseases and Sciences, 2007, 52, 2601-2609.	1.1	37
125	\tilde{A} %-valuation non invasive de la fibrose h \tilde{A} ©patique au cours des co-infections VIH et VHC et/ou VHB. Journal Africain D'Hepato-Gastroenterologie, 2007, 1, 54-58.	0.0	0
126	Current management of the complications of portal hypertension: variceal bleeding and ascites. Cmaj, 2006, 174, 1433-1443.	0.9	55

#	Article	IF	CITATIONS
127	Characteristics of patients with chronic hepatitis B in France: Predominant frequency of HBe antigen negative cases. Journal of Hepatology, 2006, 45, 355-360.	1.8	96
128	Late onset of Wilson??s disease in a family with genetic haemochromatosis. European Journal of Gastroenterology and Hepatology, 2006, 18, 43-47.	0.8	22
129	Radiofrequency thermal ablation of liver carcinoma. Gastroenterologie Clinique Et Biologique, 2006, 30, 130-135.	0.9	9
130	Sources of variability in histological scoring of chronic viral hepatitis. Hepatology, 2005, 41, 257-264.	3.6	471
131	A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology, 2005, 42, 1373-1381.	3.6	482
132	Vascular involvement of the liver in Turner's syndrome. Hepatology, 2004, 39, 239-247.	3.6	110
133	New Doppler ultrasound signs improve the non-invasive diagnosis of cirrhosis or severe liver fibrosis. European Journal of Gastroenterology and Hepatology, 2004, 16, 743-751.	0.8	62
134	Hemodynamic effects of acute and chronic administration of vapreotide in rats with cirrhosis. Digestive Diseases and Sciences, 2003, 48, 154-161.	1.1	3
135	Respective roles of porto-septal fibrosis and centrilobular fibrosis in alcoholic liver disease. Journal of Pathology, 2003, 201, 55-62.	2.1	65
136	Hepatitis C, alpha interferon, anxiety and depression disorders: A prospective study of 71 patients. World Journal of Biological Psychiatry, 2003, 4, 115-118.	1.3	74
137	Evaluation of Baveno recommendations for grading esophageal varices. Journal of Hepatology, 2003, 39, 658-659.	1.8	36
138	Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats*. Critical Care Medicine, 2003, 31, 215-220.	0.4	142
139	Inter-observer and intra-observer variability in hepatology. European Journal of Gastroenterology and Hepatology, 2003, 15, 959-966.	0.8	63
140	Prothrombin index is an indirect marker of severe liver fibrosis. European Journal of Gastroenterology and Hepatology, 2002, 14, 1133-1141.	0.8	75
141	Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. Journal of Hepatology, 2002, 37, 773-780.	1.8	105
142	Fractal dimension can distinguish models and pharmacologic changes in liver fibrosis in rats. Hepatology, 2002, 36, 840-849.	3.6	1
143	Diagnostic des hépatopathies et de leur sévérité. IRBM News, 2002, 23, 41-48.	0.1	2
144	Fractal dimension can distinguish models and pharmacologic changes in liver fibrosis in rats. Hepatology, 2002, 36, 840-849.	3.6	48

#	Article	IF	CITATIONS
145	Early Administration of Vapreotide for Variceal Bleeding in Patients with Cirrhosis. New England Journal of Medicine, 2001, 344, 23-28.	13.9	218
146	New method of cardiac output measurement using ultrasound velocity dilution in rats. Journal of Applied Physiology, 2001, 91, 1274-1282.	1.2	19
147	Interferon alpha therapy in haemophilic patients with chronic hepatitis C: a French multicentre pilot study of 58 patients. European Journal of Gastroenterology and Hepatology, 2001, 13, 859-864.	0.8	7
148	Effects of octreotide on intestinal transit and bacterial translocation in conscious rats with portal hypertension and liver fibrosis. Digestive Diseases and Sciences, 2001, 46, 2367-2373.	1.1	11
149	Hepatic hyper-vitaminosis A. European Journal of Gastroenterology and Hepatology, 2000, 12, 361-364.	0.8	23
150	Gastric Mucosal Surface In Cirrhosis Evaluated By Magnifying Endoscopy And Scanning Electronic Microscopy. Endoscopy, 2000, 32, 614-623.	1.0	10
151	Prospective study on the application of the Baveno II Consensus Conference criteria in patients with cirrhosis and gastrointestinal bleeding. Journal of Hepatology, 2000, 33, 738-741.	1.8	29
152	Spleno-renal shunt blood flow is an accurate index of collateral circulation in different models of portal hypertension and after pharmacological changes in rats. Journal of Hepatology, 2000, 32, 434-440.	1.8	13
153	Long-term administration of PGE1 increases liver fibrosis and collateral blood flow in bile-duct-ligated rats. Journal of Hepatology, 1999, 30, 70-76.	1.8	14
154	Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. Journal of Hepatology, 1999, 30, 472-478.	1.8	237
155	Non-invasive diagnosis of esophageal varices in chronic liver diseases. Journal of Hepatology, 1999, 31, 867-873.	1.8	157
156	Relationship between vascular reactivity in vitro and blood flows in rats with cirrhosis. Clinical Science, 1999, 97, 313.	1.8	8
157	Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis. European Journal of Gastroenterology and Hepatology, 1999, 11, 741.	0.8	144
158	Splenorenal shunt blood flow by transit-time ultrasound as an index of collateral circulation in portal hypertensive rats. Hepatology, 1998, 28, 1269-1274.	3.6	12
159	Antifibrotic and hemodynamic effects of the early and chronic administration of octreotide in two models of liver fibrosis in rats. Hepatology, 1998, 28, 1525-1531.	3.6	51
160	Apoptosis and liver fibrosis: antifibrotic strategies. Biomedicine and Pharmacotherapy, 1998, 52, 259-263.	2.5	18
161	Gastroesophageal endoscopic signs of cirrhosis: independent diagnostic accuracy, interassociation, and relationship to etiology and hepatic dysfunction. Gastrointestinal Endoscopy, 1998, 48, 148-157.	0.5	16
162	Effects of long-term administration of interferon \hat{l}_{\pm} in two models of liver fibrosis in rats. Journal of Hepatology, 1998, 29, 263-270.	1.8	59

#	Article	IF	Citations
163	Hemodynamic effects of terlipressin and octreotide administration alone or in combination in portal hypertensive rats. Journal of Hepatology, 1998, 29, 103-111.	1.8	22
164	Should measurements of hemodynamics in portal hypertension be dynamic?. Journal of Hepatology, 1998, 29, 829-831.	1.8	3
165	Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Journal of Hepatology, 1998, 28, 439-446.	1.8	189
166	Reproducibility in Ultrasonic Characterization of Carotid Plaques. Cerebrovascular Diseases, 1998, 8, 273-277.	0.8	57
167	Effects of positive pressure on both femoral venous and arterial blood velocities and the cutaneous microcirculation of the forefoot. Cardiovascular Research, 1997, 36, 372-376.	1.8	7
168	Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology, 1997, 113, 1609-1616.	0.6	349
169	Prevention of portal hypertension by propanolol and spironolactone in rats with bile duct ligation. Journal of Hepatology, 1997, 26, 167-173.	1.8	29
170	Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation. Journal of Hepatology, 1997, 26, 1363-1371.	1.8	56
171	Endoscopic detection of early esophageal cancer in a high-risk population: does Lugol staining improve videoendoscopy?. Gastrointestinal Endoscopy, 1997, 45, 480-484.	0.5	97
172	Interobserver agreement on endoscopic diagnosis of bleeding peptic ulcers. Gastrointestinal Endoscopy, 1997, 46, 27-32.	0.5	30
173	Liver haemangioma and pregnancy. Lancet, The, 1996, 347, 1693-1694.	6.3	3
174	Lésions muqueuses gastriques de l'hypertension portale. Acta Endoscopica, 1995, 25, 327-335.	0.0	0
175	Severe portal hypertensive gastropathy and antral vascular ectasia are distinct entities in patients with cirrhosis. Gastroenterology, 1995, 108, 138-144.	0.6	238
176	Weakness of mucosal barrier in portal hypertensive gastropathy of alcoholic cirrhosis. Effects of propranolol and enprostil. Journal of Hepatology, 1995, 23, 689-696.	1.8	28
177	Colonic investigations in the elderly: Colonoscopy or barium enema?. Aging Clinical and Experimental Research, 1995, 7, 190-194.	1.4	16
178	Prevention of relapse in patients with chronic non-A, non-B/C hepatitis who respond to alpha-interferon. A controlled multicenter trial of low-dose maintenance therapy. Journal of Hepatology, 1994, 21, 774-778.	1.8	9
179	Hemodynamic and pharmacokinetic study of tertatolol in patients with alcoholic cirrhosis and portal hypertension. Journal of Hepatology, 1993, 19, 43-50.	1.8	5
180	Propranolol in the prevention of ascites. Lancet, The, 1991, 338, 509-510.	6.3	1

#	Article	IF	CITATIONS
181	Prevention of recurrent variceal bleeding in alcoholic cirrhotic patients: prospective controlled trial of propranolol and sclerotherapy. Journal of Hepatology, 1991, 12, 283-289.	1.8	69
182	Spontaneous regression of esophageal varices is a phenomenon that has spontaneously disappeared from our memory. Journal of Hepatology, 1991, 12, 263-264.	1.8	3
183	Beta-Adrenergic–Antagonist Drugs in the Prevention of Gastrointestinal Bleeding in Patients with Cirrhosis and Esophageal Varices. New England Journal of Medicine, 1991, 324, 1532-1538.	13.9	485
184	Gastroesophageal endoscopic features in cirrhosis. Gastroenterology, 1990, 98, 156-162.	0.6	190
185	Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Journal of Hepatology, 1990, 11, 16-21.	1.8	52
186	Î ² -blockers and variceal haemorrhage. Lancet, The, 1990, 336, 506.	6.3	5
187	Propranolol in the Primary Prevention of Upper Gastrointestinal Tract Haemorrhage in Patients with Cirrhosis of the Liver and Oesophageal Varices 1. Drugs, 1989, 37, 52-61.	4.9	3
188	Verapamil has no effect on porto-hepatic pressure gradient, hepatic blood flow and elimination function of the liver in patients with liver cirrhosis. Journal of Hepatology, 1989, 8, 302-307.	1.8	17
189	Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension British Journal of Clinical Pharmacology, 1989, 27, 763-770.	1.1	22
190	Effect of propranolol on metabolic activity of the liver in patients with alcoholic cirrhosis. Journal of Hepatology, 1988, 7, 186-192.	1.8	25
191	Alteration in response of the portal tributary vascular bed to the \hat{l}^2 -agonist dobutamine in rats with extrahepatic portal hypertension. Journal of Hepatology, 1986, 2, 267-275.	1.8	6
192	Acute effect of propranolol on splanchnic circulation in normal and portal hypertensive rats. Journal of Hepatology, 1985, 1, 349-357.	1.8	39
193	Superior portosystemic collateral circulation estimated by azygos blood flow in patients with cirrhosis. Journal of Hepatology, 1985, 1, 37-46.	1.8	159
194	Session 1: Definition of Key Events– Last Attempt?. , 0, , 11-39.		3